The trial also included about 4% of patients with a BMI of between 27 and 30, in the overweight category, with at least one weight-related health condition. Retatrutide adds yet a third target, glucagon, giving it the moniker “triple G.” In this mid-stage trial, Lilly enrolled about 340 adults with obesity, who had a body mass index of at least 30. Eli Lilly’s Mounjaro, cleared for type 2 diabetes and awaiting FDA approval for weight loss, targets both GLP-1 and a hormone called GIP, and has produced weight loss of 21 to 23%. Novo Nordisk’s Ozempic, approved for type 2 diabetes, and Wegovy, cleared for weight loss, mimic just one hormone, called GLP-1, and have shown up to 15% weight loss in trials. These drugs mimic gut hormones to curb appetite and slow stomach emptying, and are administered as once-weekly injections, although pill versions are in development as well. Daily pill from Eli Lilly leads to 15% weight loss in midstage study, rivaling Wegovy results without the shot
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |